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Immune checkpoint inhibitors have changed the paradigm 
of treatment options for non-small cell lung cancer (NSCLC). 
Monoclonal antibodies targeting programmed death-1 (PD-
1) and programmed death ligand-1 (PD-L1) have gained 
wide attention for their application, which has been shown 
to result in prolonged survival. Nevertheless, only a limited 
subset of patients show partial or complete response to 
PD-1 therapy, and patients who show a response eventually 
develop resistance to immunotherapy. This article aims 
to provide an overview of the mechanisms of acquired 
resistance to anti–PD-1/PD-L1 therapy from the perspective 
of tumor cells and the surrounding microenvironment. In 
addition, we address the potential therapeutic targets and 
ongoing clinical trials, focusing mainly on NSCLC.
Keywords: acquired resistance, immune checkpoint 
inhibitors, non-small cell lung cancer, programmed death-1, 
programmed death ligand-1 
INTRODUCTION
Immune checkpoint inhibitors (ICIs) that target cytotoxic T 
lymphocyte associated antigen-4 (CTLA-4), PD-1, and PD-L1 
receptors have been shown to have beneficial therapeutic ef-
fects in lung cancer (Steven et al., 2016). ICIs are the first-line 
treatment for non-small cell lung cancer (NSCLC) with posi-
tive PD-L1 expression (Ettinger et al., 2019). However, only 
20% to 30% of NSCLC patients are sensitive to anti–PD-1/
PD-L1 therapy, and most patients experience resistance to 
immunotherapy (Pourmir et al., 2020). Acquired resistance is 
defined as disease progression within 6 months after a period 
of clinical benefit (Remon et al., 2020; Sharma et al., 2017). 
The mechanisms of acquired resistance remain to be fully 
elucidated, as research on treatment strategies to overcome 
resistance to approved immunotherapies is ongoing (Bagchi 
et al., 2021). Here, we discuss the mechanisms of acquired 
resistance to anti–PD-1/PD-L1 therapy in NSCLC, including 
loss of immunogenic neoantigens, upregulation of alternate 
immune checkpoint receptors, increase in immunosuppres-
sive cells, cytokines, and immunoregulatory molecules in the 
tumor microenvironment, and epigenetic modifications. In 
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addition, we have summarized the potential therapeutic tar-
gets and ongoing clinical trials.
MECHANISMS OF ACQUIRED RESISTANCE TO  
ANTI–PD-1/PD-L1
Loss of immunogenic neoantigen
B2M and MHC defects
Defects in beta-2-microglobulin (B2M) or major histocom-
patibility complex (MHC) molecules can cause decreased 
neoantigen presentation (Mariathasan et al., 2018; Sucker 
et al., 2014). B2M stabilizes the alpha subunits of the MHC-I 
protein, and a mutation in the B2M gene results in loss of 
neoantigen surface expression (Gettinger et al., 2017; Za-
retsky et al., 2016). In NSCLC, acquired homozygous loss of 
B2M results in a lack of MHC-I expression on the cell surface, 
which results in acquired resistance to PD-1 therapy (Getting-
er et al., 2017). In addition to loss of heterozygosity, deletions 
or point mutations in the B2M gene have been found to be 
important pathways for both primary and acquired resistance 
to ICIs (Gettinger et al., 2017; Pereira et al., 2017).
Defects in the IFN-γ pathway
Activated T cells and natural killer (NK) T cells release inter-
feron-gamma (IFN-γ) into the tumor microenvironment and 
affect immune reactions through the downstream enzymes 
Janus kinase 1 and 2 (JAK1 and JAK2) and signal transducer 
and activators of transcription (STATs) (Taube et al., 2012). 
IFN-γ stimulates antigen production, upregulation of PD-L1 
expression in tumor cells, and production of T cell-attract-
ing chemokines (Abiko et al., 2015). Deficiencies in IFN-γ, 
JAK1/2, or STATs prevent IFN-γ signaling and consequently 
result in downregulation of T cell infiltration, and decrease in 
PD-L1 and MHC-I expression (Bach et al., 1997; Sucker et al., 
2017). In patients with melanoma, JAK1- or JAK2-inactivat-
ing mutations lead to acquired resistance to anti–PD-1 ther-
apy via inhibition of the IFN-γ pathway and PD-L1 expression 
(Shin et al., 2017). Loss of PD-L1 expression is associated with 
less effective PD-1 blocking (Ren et al., 2020). Other IFN-γ 
pathway-related gene mutations, such as deletion of IFN-γ re-
ceptor 1 and 2 (IFNGR1 and 2), STAT2, JAK1, and JAK2, also 
result in acquired resistance in melanoma (Manguso et al., 
2017; Ren et al., 2020).
 Targeting downstream factors, such as JAK1/2 and STAT, is 
a possible treatment option to overcome acquired resistance 
to anti–PD-1 therapy in lung cancer (Table 1). A combination 
of JAK-STAT or vascular endothelial growth factor (VEGF) in-
hibitors and immune checkpoint therapy can help control tu-
mor growth in phosphatase and tensin homolog (PTEN)-me-
diated acquired resistance to immune checkpoint monother-
apy (Peng et al., 2016; Toso et al., 2014). Dual inhibition of 
the JAK1,2/PD-L1 and STAT3/PD-L1 signaling pathways led 
to better immune cytolytic activity of NK cells toward hypox-
ia-induced castrate-resistant prostate cancer (CRPC) cells (Xu 
et al., 2018). However, the combination of anti–PD-1 therapy 
with JAK/STAT inhibitors has also been shown to reduce an-
ti-tumor effects and tumor infiltrating lymphocyte (TIL) num-
bers (Ashizawa et al., 2019).
Upregulation of other immune checkpoint receptors
Immune checkpoint receptors are upregulated as a compen-
satory mechanism after immunotherapy. These mechanisms 
include T cell exhaustion, proliferation, migration, and cyto-
kine secretion by CD8+ T cells (Thommen et al., 2015; Topa-
lian et al., 2015). Immune checkpoints such as lymphocyte 
activation gene-3 (LAG-3), T cell immunoglobulin and mucin 
domain 3 (TIM-3), and T cell immunoreceptors with Ig and 
Table 1. Mechanisms of acquired resistance and potential therapeutic approaches
Resistance mechanisms Description of resistance mechanisms Potential therapeutic approaches
Loss of immunogenic neoantigen Defects in IFN-γ pathway STING agonist, JAK inhibitor, STAT inhibitor
Upregulation of alternate immune 
checkpoint receptors
Compensatory upregulation of inhibitory receptors 
(LAG-3, TIM-3, TIGIT, BTLA, VISTA, SIGLEC9) 
Blockade of alternate coinhibitory immune  
checkpoint receptors: LAG-3, TIM-3, TIGIT, 
BTLA, VISTA, SIGLEC9
Immune stimulatory agents: OX40, ICOS
Immunosuppressive cells and 
immunoregulative molecules in 
tumor microenvironment
Increased immunosuppressive cells  
(Treg, MDSC, M2 macrophage)
CSF1R inhibitor, TGF-β inhibitor
Elevated immunosuppressive cytokines  
(TGF-β, VEGF, IL-6/8)
TGF-β inhibitor, VEGF inhibitor, IL-1β inhibitor,  
IL-6/8 inhibitor
Immunoregulative molecules: adenosine pathway, 
IDO1, B7-H4
A2AR inhibitor/anti-CD73, IDO inhibitor, B7-H4 
inhibitor
Epigenetic modification Tumor suppressor, apoptosis gene modification Epigenetic modulators: DNMTi, HMTi, HDACi
Adoptive T cell therapyStability of chromatin remodeling complexes
IFN-γ, interferon-γ; STING, stimulator of IFN genes; JAK, Janus kinase; STAT, signal transducer and activators of transcription; LAG-3, lym-
phocyte-associated gene 3; TIM-3, T-cell immunoglobulin and mucin domain-3; TIGIT, T-cell immunoglobulin and ITIM domain; BTLA, B 
and T-lymphocyte attenuator; VISTA, V-domain immunoglobulin suppressor of T-cell activation; SIGLEC9, sialic acid binding Ig-like lectin 
9; ICOS, inducible T-cell costimulator; Treg, regulatory T-cell; MDSC, myeloid-derived suppressor cell; CSF1R, colony stimulating factor 1 
receptor; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor; IL, interleukin; IDO, indoleamine 2,3-dioxygen-
ase; A2AR, adenosine A2A receptor; DNMTi, DNA methyltransferase inhibitor; HMTi, histone methyltransferase inhibitor; HDACi, histone 
deacetylase inhibitor. 
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ITIM domains (TIGIT) create an immunosuppressive environ-
ment (Fig. 1, Table 1) (Toor et al., 2020). LAG-3 is expressed 
on TILs, and dual blockade of LAG-3 and PD-1 resulted in syn-
ergistic anti-tumor effects in preliminary models (Hellmann et 
al., 2016). TIM-3 was upregulated in both CD4+ and CD8+ 
T cells in patients with lung cancer refractory to anti–PD-1 
therapy (Koyama et al., 2016). Similarly, TIGIT expression on 
tumor antigen-specific CD8+ T cells was observed in patients 
with melanoma after anti–PD-1 treatment (Chauvin et al., 
2015).
 Other immune checkpoint receptors such as B and T 
lymphocyte attenuator (BTLA), V-domain immunoglobu-
lin-containing suppressor of T cell activation (VISTA), and 
sialic acid-binding Ig-like lectin 9 (SIGLEC9) are also potential 
treatment targets (Galon and Bruni, 2019). Similarly, immune 
stimulatory agents such as OX40 and inducible T cell costim-
ulatory (ICOS) agonists enhance T cell expansion and effector 
functions by controlling the tumor suppressive function of 
regulatory T cells (Tregs) (Hu-Lieskovan and Ribas, 2017; Ma-
honey et al., 2015).
Suppressive tumor microenvironment
Immunosuppressive cells
In patients refractory to anti–PD-1 therapy, decreased T cell 
effector function is associated with an increase in immuno-
suppressive cells such as Tregs, myeloid-derived suppressor 
cells (MDSCs), and tumor associated macrophages (TAM) 
(Fig. 1, Table 1) (Arlauckas et al., 2017). Tregs directly inhibit 
effector T cells (Teff) or produce inhibitory cytokines, such as 
interleukin (IL)-10, IL-35, and transforming growth factor-β 
(TGF-β), which suppress CD8+ T cells, resulting in acquired 
resistance to ICIs (Sakaguchi et al., 2008; Saleh and Elkord, 
2019). MDSCs induce acquired resistance to ICIs via direct 
action on T cells, promotion of tumor angiogenesis, and re-
cruitment of immune suppressive cells to the tumor microen-
vironment (Hou et al., 2020). MDSCs in the tumor microenvi-
ronment are related to a lack of response to immunotherapy 
(Meyer et al., 2014). M2 macrophages reshape the tumor 
microenvironment into a pro-tumorigenic environment 
(Chanmee et al., 2014). The colony-stimulating growth factor 
1 receptor (CSF1R) plays a critical role in differentiation, pro-
Fig. 1. Immune suppressive and immune stimulatory cell-favored niche. The immune suppressive environment (left) shows the 1) 
immune suppressive cells including Tregs and MDSCs, 2) the expression of immune suppressive cytokines, and 3) upregulation of immune 
checkpoint receptors such as TIGIT, LAG-3, and TIM-3 by T cells. The immune stimulatory environment includes PD-1 expression by T cells 
(right). The immune suppressive cell-favored niche does not respond well to ICIs, while the immune stimulatory responds favorably to ICIs.
366  Mol. Cells 2021; 44(5): 363-373
Overcoming Anti–PD-1/PD-L1 Therapy Resistance in NSCLC
Yong Jun Lee et al.
liferation, and survival of the mononuclear phagocyte system 
and macrophages (Stanley and Chitu, 2014). Blocking CSF1R 
results in a decrease in tumor-associated microphages, and 
addition of CSF1R inhibitor with PD1 and CTLA4 antagonists 
improves the response to ICIs in pancreatic cancer mouse 
models (Zhu et al., 2014), suggesting CSF1R inhibitor as a 
therapeutic approach for immunotherapy resistance.
Immunosuppressive cytokines
The upregulation of the TGF-β pathway promotes the immu-
nosuppressive effects of Tregs (Table 1) (Neel et al., 2012). 
Inhibition of TGF-β provided a better anti-tumor response to 
ICIs in a colorectal cancer model, followed by application of a 
TGF-β inhibitor with or without anti–CTLA-4 or radiation ther-
apy (Fig. 1) (Hanks et al., 2014; Vanpouille-Box et al., 2015).
 VEGF signaling activates the infiltration of Tregs into the 
tumor microenvironment and induces exhaustion of cyto-
toxic T lymphocytes (CTLs) by increasing inhibitory receptor 
expression (Voron et al., 2015). Patients with anti–PD-1 resis-
tance have higher levels of VEGF than anti–PD-1 responsive 
patients (Chen et al., 2016). Combined anti-VEGF/anti–PD-L1 
therapy has been shown to have beneficial outcomes in small 
cell lung cancer (SCLC) mouse models (Meder et al., 2018). 
These results suggest that the addition of VEGF inhibitors 
may improve the response to immunotherapy.
 IL-6 and IL-8 are proinflammatory cytokines that are found 
in the tumor microenvironment. IL-6 decreases PD-L1 and 
MHC class 1 expression, leading to tumor evasion and ICI 
therapy resistance (Garcia-Diaz et al., 2017). IL-8 modulates 
chemotaxis of neutrophils, resulting in pro-tumorigenic ef-
fects (Alfaro et al., 2016). High concentrations of IL-8 inhibit 
T cell function and antigen presentation, thereby promoting 
resistance to ICI therapy (Yuen et al., 2020).
Immunoregulative molecules
Immunoregulatory molecules such as adenosine, indoleam-
ine 2,3-dioxygenase 1 (IDO1), and B7-H4 contribute to 
immunosuppression, which is associated with ICI resistance 
(Table 1) (Platten et al., 2015; Zang et al., 2003; Zhang et 
al., 2004). Adenosine inhibits effector T cells and increases 
Tregs via adenosine A2A receptor (A2AR) binding, leading to 
a decrease in NK cell maturation and its action (Young et al., 
2018). Blocking CD73 or A2AR prevents adenosine signaling 
and improves the response of tumor cells to anti–PD-1 ther-
apy (Vijayan et al., 2017). IDO1 is an enzyme that converts 
tryptophan to kynurenine. Consumption of tryptophan and 
accumulation of kynurenine activates Teff and Tregs, and pro-
motes Treg cell formation (Ricciuti et al., 2019). Combination 
of IDO inhibitors with ICI therapy enhances the TIL function 
and number in the tumor microenvironment (Spranger et al., 
2014). B7-H4 binds to T cells and inhibits their proliferation, 
cytotoxic action, and interleukin secretion by T cells (Zang et 
al., 2003). In patients with advanced NSCLC, high expression 
of B7-H4 is associated with tumor progression and tumor-re-
lated death risks (Genova et al., 2019). The effect of B7-H4 
on immunotherapy resistance remains to be fully elucidated.
Epigenetic modification
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immunity, including T cell function, migration, exhaustion, 
and neoantigen expression (Wang et al., 2020). Epigenetic 
modifications silence tumor suppressor and apoptosis genes, 
thereby activating tumor proliferation (Table 1) (Baxter et 
al., 2014). For instance, the switch/sucrose non-fermentable 
(SWI/SNF) chromatin remodeling complex decreases the sen-
sitivity of tumor cells to CTLs, leading to a lack of response to 
immunotherapy (Miao et al., 2018; Pan et al., 2018). Several 
studies have demonstrated that re-invigoration of exhausted 
CD8+ T cells and memory T cells is feasible via chromatin re-
modeling and epigenetic modification (Fig. 1) (Jenkins et al., 
2018; Pauken et al., 2016; Ribas et al., 2016).
POTENTIAL THERAPEUTIC STRATEGIES FOR 
OVERCOMING ACQUIRED RESISTANCE
Clinical trials on the IFN-γ pathway
Several clinical trials targeting JAK1/2 and STAT are ongoing. 
In a phase 1/2 study, AZD4205, a JAK1-selective inhibitor, 
was administered as both monotherapy and combina-
tion therapy with osimertinib in advanced NSCLC patients 
(NCT03450330). A phase 1/2 clinical trial of SC-43, an SHP-
1 agonist that inhibits STAT3, in combination with cisplatin 
therapy for NSCLC is ongoing (NCT04733521).
 Activation of stimulator of IFN genes (STING) showed 
an increase in anti-tumor immunity via the upregulation of 
proinflammatory chemokines and cytokines, including type 
I IFNs (Su et al., 2019). STING agonists are a promising op-
tion for patients with resistance to immunotherapy. Clinical 
trials of STING agonists for solid tumors, such as E7766, 
GSK3745417, and MIW815, are ongoing (NCT04144140, 
NCT03843359, and NCT03172936, respectively).
Clinical trials targeting other immune checkpoints
Randomized, double-blind, and phase 2 clinical trial of an-
ti-TIGIT antibody tiragolumab in combination with atezolizum-
ab (PD-L1 inhibitor) compared with placebo plus atezolizumab 
in patients with PD-L1-selected NSCLC (CITYSCAPE) revealed 
improvement in overall response rates (ORR; 31.3% for ti-
ragolumab group and 16.2% for placebo group) and mean 
progression free survival (mPFS; 5.4 months for tiragolumab 
group and 3.6 months for placebo group) (Rodriguez-Abreu 
et al., 2020). Other agents targeting immune checkpoint re-
ceptors are currently under investigation (Table 2).
Clinical trials targeting tumor microenvironment
The A2AR antagonist CPI-444 showed anti-tumor effects as 
both monotherapy and combination therapy with atezoli-
zumab in patients with anti–PD-1/PD-L1 treatment-refractory 
renal cell carcinoma (RCC) and NSCLC, with a disease control 
rate of 36% for monotherapy in NSCLC and 71% for com-
bination therapy in NSCLC (Fong et al., 2017). Other agents 
targeting the tumor microenvironment, such as CSF1R, 
TGF-β, VEGF, IL-1/6, A2AR, CD73, IDO1, and B7-H4 inhibi-
tors, are listed in Table 2.
Clinical trials on epigenetic modification
Epigenetic modifications include DNA methylation and his-
tone (Kim et al., 2020). DNA methylation is mediated by 
DNA methyltransferase (DNMT), which regulates silencing of 
genes and non-coding genomic regions. Histone modifica-
tion enzymes such as histone methyltransferase (HMT) and 
histone deacetylase (HDAC) change the structure of chroma-
tin, leading to gene regulation and carcinogenesis (Kanwal 
and Gupta, 2012). Epigenetic modification enzyme inhibitors 
such as DNA methyltransferase inhibitors (DNMTis), histone 
methyltransferase inhibitors (HMTis), and histone deacetyl-
ase inhibitors (HDACis) are potential therapeutic targets for 
immunotherapy resistance (Arenas-Ramirez et al., 2018). 
Preclinical studies have shown that both DNMTi and HDACi 
increase the response to anti–PD-1 therapy in various tumors 
(Mazzone et al., 2017). One of the histone methyltransferase 
enzymes, enhancer of zeste homolog 2 (EZH2), is involved in 
the proliferation, migration, and invasion of various cancer 
cells such as glioblastoma, ovarian cancer, and prostate can-
cer (Yamaguchi and Hung, 2014). EZH2 exhibited a silencing 
effect on antigen presentation and immune reaction, and 
blocking of EZH2 resulted in synergistic effects with anti–
CTLA-4 and IL-2 immunotherapy (Zingg et al., 2017).
 For patients with relapsed or refractory malignant meso-
thelioma, the EZH2 inhibitor tazemetostat was well tolerated 
and showed a 47% disease control rate in 12 patients (Zau-
derer et al., 2020). A phase 1/2 clinical trial of tazemetostat 
monotherapy in patients with advanced solid tumors or B-cell 
lymphomas is currently underway (NCT01897571). Other 
clinical trials for epigenetic modulators such as DNMTis, HM-
Tis, HDACis, and adoptive T cell therapy are included in Table 
2.
CONCLUSION
The advent of immunotherapy has changed the treatment 
options in NSCLC. Prior to immunotherapy and targeted 
agents, chemotherapy was the backbone of treatment. Cur-
rently, the first line standard treatment for stage IV NSCLC is 
anti–PD-1 with or without chemotherapy, with the addition 
of chemotherapy depending on the PD-L1 expressions of 
the patients (Mok et al., 2019). There is also the option of 
anti–PD-L1 and VEGFR inhibitor with chemotherapy in first 
line non-squamous NSCLC (Socinski et al., 2018). Recently, 
front-line nivolumab with ipilimumab in combination with 
short course chemotherapy showed overall survival benefit 
in patients with NSCLC and received U.S. Food and Drug 
Administration approval (Arenas-Ramirez et al., 2018). Un-
precedented results of survival gain in NSCLC have acceler-
ated scientists and clinicians to explore various combinations 
of immunotherapy with other agents in order to overcome 
acquired resistance. Indeed, elucidating the mechanisms un-
derlying acquired resistance is necessary to provide treatment 
options for this subset of patients. Notably, the upregulation 
IFN-γ pathway, co-inhibition of immune checkpoints such as 
TIGIT, and inhibition of TGF-β have gained attention as prom-
ising potential therapeutic strategies and are awaiting results.
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